Misplaced Pages

Benzofluorene

Names
Preferred IUPAC name 7H-Benzofluorene
Other names Tetracycloheptadeca-1,3,5,7,9,12,14,16-octaene
Identifiers
CAS Number	205-12-9
ChEBI	CHEBI:82403
ChemSpider	8796
ECHA InfoCard	100.005.372
EC Number	205-908-2
KEGG	C19344
PubChem CID	915
UNII	PX3702DW3A
CompTox Dashboard (EPA)	DTXSID30874039
Properties
Chemical formula	C17H12
Molar mass	216.283 g·mol
Density	1.185 g/cm
Melting point	125–127 °C (257–261 °F; 398–400 K) predicted
Boiling point	398 °C (748 °F; 671 K) predicted
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Y verify (what is  ?) Infobox references

Benzofluorene is a polycyclic aromatic hydrocarbon (PAH) with mutagenic activity. It is a component of coal tar, cigarette smoke and smog and thought to be a major contributor to its carcinogenic properties. The mutagenicity of benzofluorene is mainly attributed to formation of metabolites that are reactive and capable of forming DNA adducts. According to the KEGG it is a group 3 carcinogen (not classifiable as to its carcinogenicity to humans). Other names for benzofluorene are 7H-benzofluorene, 3,4-benzofluorene, and NSC 89264.

Structure and reactivity

The structure of benzofluorene is depicted in the infobox on the right. It is an aromatic fluorene-derived molecule with an extra benzene ring. This benzene ring is attached to carbon 3 and 4 of the fluorene-derived molecule. The 3D structure of benzofluorene is depicted in the infobox on the right as well. It is mostly flat, because it consists of 3 aromatic rings. Only the 2 hydrogen atoms on the 5 ring are oriented into the 3D plane.

Synthesis

Benzofluorene occurs naturally in tar, but can also be manually synthesized in a four step process, which is depicted in the picture below. The starting product is 1-indanone (1). This is brominated in a substitution reaction to 3-bromoindanone (2) using the reagent N-bromosuccinimide. This substance is dehydrobrominated to 2H-inden-1-one (3) using the reagent triethylamine. Benzofluorenone-9 (4) is generated by self-condensation of 2H-inden-1-one, when heated. The final step is reduction of this compound with hydrazine hydrate, generating benzofluorene (5).

Metabolism

In general PAH carcinogenesis involves activation by the enzyme P-450 to diol epoxide metabolites with an epoxide ring in the bay or fjord region. These diol epoxide metabolites are reactive and capable of forming DNA adducts (see the adjacent image). While benzofluorene does not have a bay or fjord region it does undergo a similar transformation with a pseudo-bay region that reacts instead. The type of cytochrome P 450 involved is thought to be CYP1A1.

The biotransformation is depicted in the image below. First benzofluorene (1) is transformed into trans-3,4-dihydrodiol (2). This substance is transformed by CYP1A1 into the highly carcinogenic metabolites anti-diolepoxide (3) and syn-diolepoxide (4).

ADME of benzofluorene and PAHs in general

Absorption

Benzofluorene and PAHs in general are mostly absorbed via ingestion, inhalation, and dermal contact. Also, depending on the vehicle (transport medium) in which the PAHs are located, the percentages of absorption can differ. Ingestion of benzofluorene makes it a very potent lung tumorigen In particular, benzofluorene is better absorbed in the lungs.

Distribution

Once it is absorbed, benzofluorene enters the lymph, circulates in the blood and is metabolized. The distribution of PAHs depends on their lipophilicity and probably benzofluorene can easily cross the cell membrane, because of this lipophilicity. This has been proven for similar substances like fluorene and fluoranthene, but has yet to be investigated for benzofluorene.

Metabolism and excretion

Benzofluorene is mainly metabolized by the CYP enzymes in the liver. There is also evidence that a larger number of metabolites are formed in the lungs, which might explain why benzofluorene is such a potent lung tumorigen. It is possible that benzofluorene may have a unique (and still unknown) mechanism of activation or transportation, which explains why the lungs are targeted. The initial steps of the metabolism, the phase I biotransformation, are described above.

For many PAHs it has been proven that they are conjugated, in phase II, with either glucuronide, sulfate or glutathione. More research on this topic is necessary for benzofluorene. Glucuronide and sulfate conjugates of PAH metabolites are generally excreted in the bile and urine. Glutathione conjugates are further metabolized to mercapturic acids in the kidney and are excreted in the urine. The hydroxylated metabolites of the PAHs are excreted in human urine both as free hydroxylated metabolites and as hydroxylated metabolites conjugated to glucuronic acid and sulfate.

Mechanism of action

The carcinogenic metabolites of benzofluorene bind to DNA which involves the opening of the epoxide ring in benzofluorene anti- and syn-diolepoxide. The benzofluorene metabolites bind in a yet unknown fashion to the DNA.

When a DNA adduct forms at a site critical to the regulation of cell differentiation or growth it can cause cancer. If an aberration in the DNA is not well repaired by the NER, a mutation will occur during cell replication. In addition, it is known that the cells affected most appear to be those with rapid replication, such as bone marrow, skin, and lung tissue, whereas tissues with slower turnover rate like the liver are less susceptible.

Exposure to benzofluorene in vivo leads to the induction of mainly lung tumors where it acts as a DNA adductor. Lung tumors arise after topical application in mice with coal tar, but also when it is ingested. Next to its involvement in lung tumors, benzofluorene and its metabolites are expected to be involved in the formation of different tumors. The formation of DNA adducts in human breast tumors, hepatoma and colon adenocarcinoma by these metabolites has been shown in vitro. These adducts and the ones that were observed in lung tumors of mice were similar, which strengthens the hypothesis that human cells are capable of forming the mutagenic metabolites.

Environmental exposure

Benzofluorene belongs to a group of compounds called polycyclic aromatic hydrocarbons (PAHs). PAHs and their derivatives are ubiquitous in the environment and they are produced in several industrial and combustion processes.

Workers in industries or trades using or producing coal, crude oil or coal products are at highest risk for PAH exposure. In general, the PAHs are formed during these industrial processes by incomplete combustion or pyrolysis of organic matter. The higher the temperature the more PAHs are formed.

Some of these PAHs, such as benzofluorene, are carcinogens and mutagens and act as possible endocrine disruptors. To estimate the health effects that arise from exposure to PAHs and benzofluorene it is necessary to determine the concentration of these compounds in the atmosphere. This was done in a study by Morisaki et al. 2016. They compared the concentrations of different PAHs including benzofluorene in Beijing and Kanazawa in winter and summer.

The researchers corrected for the relative mutagenicity of compounds compared to benzopyrene. The results of this are presented as BaPeq, which equals the concentration of the compound, times the potency of the compound compared to benzopyrene (RPF). Although the concentrations measured of benzofluorene are quite low, when corrected for mutagenicity, benzofluorene is the most important PAH of those that were measured in terms of possible health risks.

Safety

Carcinogenity

In one study, the Ames test was performed on benzofluorene. Two different strains were used, TA100 and TA98. One group of each strain had a rat liver fraction and one group did not. The difference between the TA100 and the TA98 strain is that the TA98 strain has a frameshift mutation, and the TA100 has a base substitution mutation. When the amount of benzofluorene is increased in TA 100 yeast strain, the amount of revertants per plate does not increase. Only in the TA98 strain plate, which contained a fraction of a rat liver, a higher dose of benzofluorene seems to correspond with a larger amount of revertants. This indicates that benzofluorene is metabolized by enzymes in the rat liver into more potent mutagenic compounds. These compounds only affected the TA98 strain. This indicates that the adducts formed by benzofluorene metabolites cause frameshift mutations, and not point mutations.

Dose response curve of benzofluorene was applied to the skin of mice. Data derived from	Ames test of benzofluorene. Data derived from

Effects on animals

In one animal study, mice that were fed coal tar developed lung tumors. DNA adducts in these mice were analyzed and could be traced back to benzofluorene. This and another similar study suggest a contribution of benzofluorene to the carcinogenic potency of coal tar when administered orally.

Another study found that benzofluorene is also carcinogenic in mice when applied topically, inducing lung and skin cancer. Of the results of this study a dose-response curve has been made, see the image above.

This figure shows the DNA adduct level after a certain dose of benzofluorene was applied to the skin of mice. This level is similar in the lungs and in the skin implying that benzofluorene is a systemic mutagen.

The effects of exposure to benzofluorene were also researched on rats. In one of these studies the liver was established to be the main place of disposition of benzofluorene after a single oral dose regardless of the size of the dose. It was found that 55-69% of the labelled benzofluorene was excreted via the feces while 8–10% was found to be eliminated via urine. While the benzofluorene found in the feces was not biotransformed, the urine samples mainly showed polar metabolites of benzofluorene.

See also

• Benzofluorene

References

1. ^ Koganti A, Singh R, Rozett K, Modi N, Goldstein LS, Roy TA, Zhang FJ, Harvey RG, Weyand EH (2000). "7H-benzo[c]fluorene: a major DNA adduct-forming component of coal tar". Carcinogenesis. 21 (8): 1601–1609. doi:10.1093/carcin/21.8.1601. PMID 10910965.
2. ^ Wang JQ, Weyand EH, Harvey RG (2002). "Synthesis of suspected carcinogenic metabolites of 7H-benzofluorene, a coal tar component implicated in causation of lung tumors". J Org Chem. 67 (17): 6216–6219. doi:10.1021/jo011149b. PMID 12182663.
3. "7H-Benzo[c]fluorene". Pubchem. Retrieved 7 March 2016.
4. "Benzo[c]fluorene on Chemspider". Chemspider. Retrieved 7 March 2016.
5. "7H-Benzo[c]fluorene". trc-canada.com. Toronto Research Chemicals Toronto Research Chemicals. Retrieved 7 March 2016.
6. Created from PDB 1JDG Archived 2008-09-22 at the Wayback Machine
7. Kazlauskas K, Kreiza G, Radiunas E, Adomenas P, Adomeniene O, Karpavicius K, Bucevicius J, Jankauskas V, Jursenas S (2015). "Concentration effects on spontaneous and amplified emission in benzofluorenes". Physical Chemistry Chemical Physics. 17 (19): 12935–12948. Bibcode:2015PCCP...1712935K. doi:10.1039/C5CP01325A. PMID 25912324.
8. ^ Agency for Toxic Substances and Disease Registry (ATSDR) (2009). "Toxicity of Polycyclic Aromatic Hydrocarbons (PAH)". Retrieved 10 March 2016. {{cite journal}}: Cite journal requires |journal= (help)
9. ^ Weyand EH, Parimoo B, Reuhl KR, Goldstein LS, Wang JQ, Harvey RG (2004). "7H-Benzo[C]Fluorene: A Potent Systemic Lung Carcinogen". Polycyclic Aromatic Compounds. 24 (1): 1–20. doi:10.1080/10406630490426942. S2CID 85148344.
10. Seto H, Ohkubo T, Kanoh T, Koike M, Nakamura K, Kawahara Y (1993). "Determination of polycyclic aromatic hydrocarbons in the lung". Arch Environ Contam Toxicol. 24 (4): 498–503. doi:10.1007/bf01146169. PMID 8507106. S2CID 21678586.
11. Librando V, Sarpietro MG, Castelli F (2003). "Role of lipophilic medium in the absorption of polycyclic aromatic compounds by biomembranes". Environmental Toxicology and Pharmacology. 14 (1–2): 25–32. doi:10.1016/s1382-6689(03)00007-3. PMID 21782659.
12. Goth-Goldstein, Regine; Marion L. Russell; Bhama Parimoo & Eric H. Weyand (2002). "7H-Benzo[c]fluorene DNA adduct formation in different human cells in culture". Retrieved 10 March 2016. {{cite journal}}: Cite journal requires |journal= (help)
13. ^ Morisaki H, Nakamura S, Tang N, Toriba A, Hayakawa K (2016). "Benzo[c]fluorene in Urban Air: HPLC Determination and Mutagenic Contribution Relative to Benzo[a]pyrene". Anal Sci. 32 (2): 233–23. doi:10.2116/analsci.32.233. hdl:2297/46773. PMID 26860571.
14. "BaP and PAH from coal-derived sources" (PDF). gezondheidsraad.nl. Health Council of the Netherlands. Retrieved 7 March 2016.
15. "U.S. EPA. Development of a Relative Potency Factor (RPF) Approach for Polycyclic Aromatic Hydrocarbon (PAH) Mixtures (External Review Draft)". epa.gov. U.S. Environmental Protection Agency. Retrieved 7 March 2016.
16. ^ Lavoie EJ, Tulley L, Bedenko V, Hoffmann D (1981). "Mutagenicity of methylated fluorenes and benzofluorenes". Mutat Res. 91 (3): 167–176. doi:10.1016/0165-7992(81)90027-0. PMID 7017394.
17. ^ Cizmas L; Zhou G-d; Safe SH; McDonald TJ; Zhu L; Donnelly KC (2004). "Comparative in vitro and in vivo genotoxicities of 7H-benzofluorene, manufactured gas plant residue (MGP), and MGP fractions". Environmental and Molecular Mutagenesis. 43 (3): 159–168. doi:10.1002/em.20011. PMID 15065203. S2CID 7039355.
18. Koganti A, Singh R, Ma BL, Weyand EH (2001). "Comparative analysis of PAH:DNA adducts formed in lung of mice exposed to neat coal tar and soils contaminated with coal tar". Environ Sci Technol. 35 (13): 2704–2709. Bibcode:2001EnST...35.2704K. doi:10.1021/es001532i. PMID 11452595.
19. Chopard-Lallier M, Perdu E, Jamin E, Brochot C, Craved J (2014). "Disposition of benzo[c]fluorene in rats". Toxicology Letters. 229 (supplement): 4141. doi:10.1016/j.toxlet.2014.06.838. Retrieved 7 March 2016.

• Polycyclic aromatic hydrocarbons
• Tetracyclic compounds